Trial Profile
A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Metformin (Primary) ; Valsartan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms RESILIENCE
- Sponsors ARKAY Therapeutics
- 26 Feb 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2026.
- 26 Feb 2023 Planned primary completion date changed from 26 Nov 2023 to 26 Nov 2025.
- 26 Feb 2023 Planned initiation date changed from 11 Oct 2021 to 10 Oct 2021.